Lithium in the Acute Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled Study

• Published in: Pediatrics (Evanston) Vol. 136; no. 5; pp. 885 - 894
• Main Authors: Findling, Robert L, Robb, Adelaide, McNamara, Nora K, Pavuluri, Mani N, Kafantaris, Vivian, Scheffer, Russell, Frazier, Jean A, Rynn, Moira, DelBello, Melissa, Kowatch, Robert A, Rowles, Brieana M, Lingler, Jacqui, Martz, Karen, Anand, Ravinder, Clemons, Traci E, Taylor-Zapata, Perdita
• Format: Journal Article
• Language: English
• Published: United States American Academy of Pediatrics 01-11-2015
• Subjects: Adolescent; Antimanic Agents - therapeutic use; Bipolar disorder; Bipolar Disorder - classification; Bipolar Disorder - drug therapy; Care and treatment; Child; Children; Clinical trials; Dosage and administration; Double-Blind Method; Female; Health aspects; Humans; Lithium; Lithium Compounds - therapeutic use; Lithium drugs; Male; Medical treatment; Pediatrics; Risk factors
• ISSN: 0031-4005; 1098-4275
• DOI: 10.1542/peds.2015-0743

Lithium is a benchmark treatment for bipolar disorder in adults. Definitive studies of lithium in pediatric bipolar I disorder (BP-I) are lacking.
This multicenter, randomized, double-blind, placebo-controlled study of pediatric participants (ages 7-17 years) with BP-I/manic or mixed episodes compared lithium (n = 53) versus placebo (n = 28) for up to 8 weeks. The a priori primary efficacy measure was change from baseline to the end of study (week 8/ET) in the Young Mania Rating Scale (YMRS) score, based on last-observation-carried-forward analysis.
The change in YMRS score was significantly larger in lithium-treated participants (5.51 [95% confidence interval: 0.51 to 10.50]) after adjustment for baseline YMRS score, age group, weight group, gender, and study site (P = .03). Overall Clinical Global Impression-Improvement scores favored lithium (n = 25; 47% very much/much improved) compared with placebo (n = 6; 21% very much/much improved) at week 8/ET (P = .03). A statistically significant increase in thyrotropin concentration was seen with lithium (3.0 ± 3.1 mIU/L) compared with placebo (-0.1 ± 0.9 mIU/L; P < .001). There was no statistically significant between-group difference with respect to weight gain.
Lithium was superior to placebo in reducing manic symptoms in pediatric patients treated for BP-I in this clinical trial. Lithium was generally well tolerated in this patient population and was not associated with weight gain, distinguishing it from other agents commonly used to treat youth with bipolar disorder.